HomepageBVNKF • OTCMKTS
add
Bavarian Nordic
Vorige slotkoers
$Â 31,28
Jaar-range
$Â 17,65 - $Â 46,05
Beurswaarde
2,57Â mld. USD
Gem. volume
801,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
CPH
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(DKK) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,43Â mld. | -28,14% |
Bedrijfskosten | 454,06Â mln. | -39,99% |
Netto inkomsten | 261,13Â mln. | -51,47% |
Netto winstmarge | 18,29 | -32,48% |
Winst per aandeel | 3,30 | -53,52% |
EBITDA | 419,54Â mln. | -39,17% |
Effectief belastingtarief | 1,83% | — |
Balans
Totale activa
Totale passiva
(DKK) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 2,24Â mld. | 61,35% |
Totale activa | 14,27Â mld. | -4,79% |
Totale passiva | 3,84Â mld. | -27,69% |
Totaal aandelenvermogen | 10,44 mld. | — |
Uitstaande aandelen | 79,13 mln. | — |
Koers-boekwaardeverhouding | 0,24 | — |
Rendement op activa | 4,77% | — |
Rendement op kapitaal | 6,37% | — |
Kasstroom
Nettomutatie in liquide middelen
(DKK) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 261,13Â mln. | -51,47% |
Operationele kasstroom | 630,87Â mln. | 42,57% |
Kasstroom uit beleggingen | -650,59Â mln. | 36,99% |
Kasstroom uit financiering | -26,49Â mln. | -117,67% |
Nettomutatie in liquide middelen | -44,41Â mln. | 89,90% |
Vrije kasstroom | -242,62Â mln. | -159,79% |
Over
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany and San Diego, California, as well as offices in Zug, Switzerland, and Morrisville, North Carolina. The company uses viral vectors and virus-like particles in its research and development. Wikipedia
CEO
Opgericht
1 jul 1992
Website
Werknemers
1.381